Alliqua Inc (ALQA) 7.73 $ALQA
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
UPDATE -- Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
GlobeNewswire - Tue Apr 15, 10:14AM CDT
In a release issued earlier today under the same headline by Alliqua, Inc. (Nasdaq:ALQA), please note that details of the common stock price of $7.00 per share have been added to paragraph two. The updated release follows.
Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
GlobeNewswire - Tue Apr 15, 7:55AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or the "Company"
, a provider of advanced wound care products, has raised $20.3 million in a series of transactions that included a $15.0 million private placement of common stock and warrants and $5.3 million from the exercise of warrants from several institutional shareholders.
Alliqua Appoints 20 Direct Sales Representatives to Strengthen Brand Awareness and Drive Greater Market Penetration in the U.S.
GlobeNewswire - Mon Mar 31, 6:30AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or the "Company" , a provider of advanced wound care products, has hired a 20-member direct sales force to further strengthen the Company's brand awareness, increase brand adoption and drive greater market penetration in the United States. The new sales team members come to Alliqua with vast experience in the healthcare space and a successful history of navigating the U.S. healthcare sales cycle.
Alliqua Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 6:30AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company" , a provider of advanced wound care products and custom manufacturing solutions to partners in the medical device and cosmetics industry, reports its financial results for the quarter and year ended December 31, 2013.
EquitiesIQ Interviews David Johnson, CEO of Alliqua
ACCESSWIRE - Wed Mar 19, 12:30PM CDT
Watch the Interview: http://equitiesiq.com/alliqua-interview/
Alliqua to Present at 26th Annual ROTH Conference on March 10
GlobeNewswire - Mon Mar 03, 6:01AM CST
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company" announces that David Johnson, Chief Executive Officer, will present at the 26th Annual ROTH Conference at The Ritz-Carlton in Laguna Niguel, CA. Mr. Johnson is scheduled to present on Monday, March 10 at 2:00 pm PT (5:00 pm ET) in Track 6, Salon 6.
Alliqua, Inc. [ALQA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Feb 21, 9:00AM CST
What:
Alliqua, Inc. Profiled by TheStreet.com and Philadelphia Business Journal
Business Wire - Thu Feb 13, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or the "Company" was featured in a video interview published by TheStreet.com and in an article published by the Philadelphia Business Journal.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into ALLIQUA, INC. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Tue Feb 11, 11:01AM CST
Levi & Korsinsky, LLP is investigating Alliqua, Inc. (NasdaqCM: ALQA) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Alliqua names Janice M Smiell as company's first chief medical officer
M2 - Tue Feb 11, 7:29AM CST
US-based wound care and drug delivery specialists Alliqua Inc (Nasdaq:ALQA) announced on Monday the appointment of Janice M Smiell MD to the newly created position of chief medical officer.
SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics
PR Newswire - Tue Feb 11, 7:00AM CST
SeraCare Life Sciences, a provider of high quality biological materials and reagents that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding member of the SeraCare Science Advisory Board. This group will bring together thought leaders in emerging technologies and applications such as NexGen sequencing, clinical oncology and autoimmune disease to foster collaboration and innovation.
Alliqua Appoints Janice M. Smiell, M.D. as its First Chief Medical Officer
Business Wire - Mon Feb 10, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company" has appointed Janice M. Smiell, M.D. as its Chief Medical Officer, a newly created position.
Alliqua's CEO Issues Letter to Shareholders
Business Wire - Mon Feb 03, 6:30AM CST
David Johnson, CEO of Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company" , has issued the following letter to shareholders:
10-Q: MISTRAS GROUP, INC.
Edgar Online - Thu Jan 09, 3:07PM CST
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Alliqua Appoints Perry A. Karsen to Board of Directors
PR Newswire - Wed Dec 04, 7:00AM CST
CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to Alliqua's Board
Alliqua Announces Transaction with Celgene
Business Wire - Tue Nov 19, 6:30AM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company" entered into a licensing agreement with Celgene Cellular Therapeutics ("CCT" , a subsidiary of Celgene Corporation (NASDAQ:CELG) ("Celgene" , whereby Alliqua received the right to develop and market the advanced wound care products Biovance(R) and Extracellular Matrix (ECM). Concurrently with the license agreement, Alliqua entered into an agreement with Celgene to sell to Celgene 1,672,474 shares of common stock of Alliqua, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In connection with this agreement to invest in Alliqua's securities, Celgene received a right to appoint a director to Alliqua's Board of Directors. Concurrent to this transaction, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested an additional $7 million on comparable financial terms. Alere Financial Partners, a division of Summer Street Research Partners, acted as placement agent for the transaction with these investors.
Alliqua Announces Reverse Split of Common Stock
Business Wire - Mon Nov 18, 4:02PM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or "the Company" announced it effected a one (1) for 43.75 reverse split of its common stock (the "Reverse Split" as a step toward the Company's intention to have its common stock listed on a national exchange.
Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
UPDATE -- Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
GlobeNewswire - Tue Apr 15, 10:14AM CDT
In a release issued earlier today under the same headline by Alliqua, Inc. (Nasdaq:ALQA), please note that details of the common stock price of $7.00 per share have been added to paragraph two. The updated release follows.
Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants
GlobeNewswire - Tue Apr 15, 7:55AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or the "Company"
, a provider of advanced wound care products, has raised $20.3 million in a series of transactions that included a $15.0 million private placement of common stock and warrants and $5.3 million from the exercise of warrants from several institutional shareholders. Alliqua Appoints 20 Direct Sales Representatives to Strengthen Brand Awareness and Drive Greater Market Penetration in the U.S.
GlobeNewswire - Mon Mar 31, 6:30AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or the "Company"
, a provider of advanced wound care products, has hired a 20-member direct sales force to further strengthen the Company's brand awareness, increase brand adoption and drive greater market penetration in the United States. The new sales team members come to Alliqua with vast experience in the healthcare space and a successful history of navigating the U.S. healthcare sales cycle. Alliqua Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 6:30AM CDT
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products and custom manufacturing solutions to partners in the medical device and cosmetics industry, reports its financial results for the quarter and year ended December 31, 2013. EquitiesIQ Interviews David Johnson, CEO of Alliqua
ACCESSWIRE - Wed Mar 19, 12:30PM CDT
Watch the Interview: http://equitiesiq.com/alliqua-interview/
Alliqua to Present at 26th Annual ROTH Conference on March 10
GlobeNewswire - Mon Mar 03, 6:01AM CST
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
announces that David Johnson, Chief Executive Officer, will present at the 26th Annual ROTH Conference at The Ritz-Carlton in Laguna Niguel, CA. Mr. Johnson is scheduled to present on Monday, March 10 at 2:00 pm PT (5:00 pm ET) in Track 6, Salon 6. Alliqua, Inc. [ALQA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Feb 21, 9:00AM CST
What:
Alliqua, Inc. Profiled by TheStreet.com and Philadelphia Business Journal
Business Wire - Thu Feb 13, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or the "Company"
was featured in a video interview published by TheStreet.com and in an article published by the Philadelphia Business Journal. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into ALLIQUA, INC. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Tue Feb 11, 11:01AM CST
Levi & Korsinsky, LLP is investigating Alliqua, Inc. (NasdaqCM: ALQA) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Alliqua names Janice M Smiell as company's first chief medical officer
M2 - Tue Feb 11, 7:29AM CST
US-based wound care and drug delivery specialists Alliqua Inc (Nasdaq:ALQA) announced on Monday the appointment of Janice M Smiell MD to the newly created position of chief medical officer.
SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics
PR Newswire - Tue Feb 11, 7:00AM CST
SeraCare Life Sciences, a provider of high quality biological materials and reagents that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding member of the SeraCare Science Advisory Board. This group will bring together thought leaders in emerging technologies and applications such as NexGen sequencing, clinical oncology and autoimmune disease to foster collaboration and innovation.
Alliqua Appoints Janice M. Smiell, M.D. as its First Chief Medical Officer
Business Wire - Mon Feb 10, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
has appointed Janice M. Smiell, M.D. as its Chief Medical Officer, a newly created position. Alliqua's CEO Issues Letter to Shareholders
Business Wire - Mon Feb 03, 6:30AM CST
David Johnson, CEO of Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, has issued the following letter to shareholders: 10-Q: MISTRAS GROUP, INC.
Edgar Online - Thu Jan 09, 3:07PM CST
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Alliqua Appoints Perry A. Karsen to Board of Directors
PR Newswire - Wed Dec 04, 7:00AM CST
CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to Alliqua's Board
Alliqua Announces Transaction with Celgene
Business Wire - Tue Nov 19, 6:30AM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company"
entered into a licensing agreement with Celgene Cellular Therapeutics ("CCT" , a subsidiary of Celgene Corporation (NASDAQ:CELG) ("Celgene" , whereby Alliqua received the right to develop and market the advanced wound care products Biovance(R) and Extracellular Matrix (ECM). Concurrently with the license agreement, Alliqua entered into an agreement with Celgene to sell to Celgene 1,672,474 shares of common stock of Alliqua, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In connection with this agreement to invest in Alliqua's securities, Celgene received a right to appoint a director to Alliqua's Board of Directors. Concurrent to this transaction, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested an additional $7 million on comparable financial terms. Alere Financial Partners, a division of Summer Street Research Partners, acted as placement agent for the transaction with these investors. Alliqua Announces Reverse Split of Common Stock
Business Wire - Mon Nov 18, 4:02PM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or "the Company"
announced it effected a one (1) for 43.75 reverse split of its common stock (the "Reverse Split" as a step toward the Company's intention to have its common stock listed on a national exchange. Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
